PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-100.00%
Revenue decline while AXSM shows 4.85% growth. Joel Greenblatt would examine competitive position erosion.
8.54%
Similar cost growth to AXSM's 10.17%. Walter Schloss would investigate if industry cost pressures are temporary.
-83.05%
Gross profit decline while AXSM shows 4.24% growth. Joel Greenblatt would examine competitive position.
No Data
No Data available this quarter, please select a different quarter.
-18.94%
R&D reduction while AXSM shows 18.78% growth. Joel Greenblatt would examine competitive risk.
28.45%
G&A growth 1.25-1.5x AXSM's 19.55%. Martin Whitman would scrutinize overhead control.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.25%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-7.93%
Both companies reducing total costs. Martin Whitman would check industry trends.
-100.00%
Interest expense reduction while AXSM shows 54.13% growth. Joel Greenblatt would examine advantage.
8.54%
D&A growth above 1.5x AXSM's 5.23%. Michael Burry would check for excessive investment.
7.52%
EBITDA growth below 50% of AXSM's 32.21%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
7.21%
Operating income growth below 50% of AXSM's 29.99%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
-9.03%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
7.01%
Pre-tax income growth below 50% of AXSM's 30.94%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
-68.42%
Tax expense reduction while AXSM shows 100.00% growth. Joel Greenblatt would examine advantage.
7.01%
Net income growth below 50% of AXSM's 30.71%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
8.82%
EPS growth below 50% of AXSM's 30.77%. Michael Burry would check for structural issues.
8.82%
Diluted EPS growth below 50% of AXSM's 30.77%. Michael Burry would check for structural issues.
0.91%
Share count reduction below 50% of AXSM's 0.13%. Michael Burry would check for concerns.
0.91%
Diluted share reduction below 50% of AXSM's 0.13%. Michael Burry would check for concerns.